Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators.
Aged
Biopsy
Breast
/ pathology
Breast Neoplasms
/ diagnosis
Early Detection of Cancer
/ standards
Europe
/ epidemiology
Female
Health Plan Implementation
/ standards
Humans
Mammography
/ standards
Mass Screening
/ organization & administration
Mastectomy
/ statistics & numerical data
Middle Aged
Patient Acceptance of Health Care
/ statistics & numerical data
Practice Guidelines as Topic
Program Evaluation
Quality Indicators, Health Care
/ standards
Time Factors
Breast neoplasms/diagnostic imaging*
Early detection of Cancer*/methods
Female
Health care/standards*
Mass screening/methods
Programme evaluation
Quality indicators
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
24 Aug 2020
24 Aug 2020
Historique:
received:
17
01
2020
accepted:
11
08
2020
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
15
4
2021
Statut:
epublish
Résumé
In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection. The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries. A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate. This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.
Sections du résumé
BACKGROUND
BACKGROUND
In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection.
METHODS
METHODS
The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries.
RESULTS
RESULTS
A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate.
CONCLUSION
CONCLUSIONS
This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.
Identifiants
pubmed: 32831048
doi: 10.1186/s12885-020-07289-z
pii: 10.1186/s12885-020-07289-z
pmc: PMC7444070
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
795Subventions
Organisme : European Commission, Joint Research Centre Ispra, Italy
ID : Not applicable
Investigateurs
Mariangela Autelitano
(M)
Edoardo Colzani
(E)
Jan Daneš
(J)
Axel Gräwingholt
(A)
Lydia Ioannidou-Mouzaka
(L)
Susan Knox
(S)
Miranda Langendam
(M)
Helen McGarrigle
(H)
Elsa Pérez Gómez
(E)
Ruben van Engen
(R)
Sue Warman
(S)
Kenneth Young
(K)
Cary van Landsveld-Verhoeven
(C)
Donata Lerda
(D)
Zuleika Saz-Parkinson
(Z)
Elena Parmelli
(E)
Annett Janusch-Roi
(A)
Références
BMJ. 2016 Jun 28;353:i2016
pubmed: 27353417
Medicine (Baltimore). 2017 Jan;96(3):e5684
pubmed: 28099330
Breast Care (Basel). 2011;6(2):104-109
pubmed: 21673820
Cancer Epidemiol. 2015 Oct;39(5):783-9
pubmed: 26315486
Acta Oncol. 2008;47(8):1618
pubmed: 18759146
J Med Screen. 2012;19 Suppl 1:14-25
pubmed: 22972807
J Med Screen. 2005;12(1):33-7
pubmed: 15814017
Eur J Cancer Prev. 2005 Apr;14(2):107-16
pubmed: 15785314
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Lancet. 2012 Nov 17;380(9855):1778-86
pubmed: 23117178
J Med Screen. 2019 Sep;26(3):120-126
pubmed: 30621498
Breast. 2017 Dec;36:89-95
pubmed: 28988610
Ann Intern Med. 2019 Aug 20;171(4):273-280
pubmed: 31330534
Br J Cancer. 2017 Mar 14;116(6):828-839
pubmed: 28183141
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Curr Oncol. 2016 Apr;23(2):81-90
pubmed: 27122972
J Med Screen. 2012;19 Suppl 1:42-56
pubmed: 22972810
Value Health. 2013 Jun;16(4):647-54
pubmed: 23796300